title: Efficacy and tolerability of a combined moxifloxacin/dexamethasone formulation for topical prophylaxis and reduction of inflammation in phacoemulsification: a comparative, double masked clinical trial.
abstract: OBJECTIVE
  To compare the efficacy and safety of a combined 0.5% moxifloxacin and 0.1% dexamethasone formulation (Vigadexa) versus conventional dosing with 0.5% concomitant moxifloxacin (Vigamox) and 0.1% dexamethasone (Maxidex) for the prevention of infection and control of inflammation after cataract surgery.
  
  
  METHODS
  The ophthalmology clinic and outpatient surgery suite of a public hospital in Brazil.
  
  
  METHODS
  A prospective, randomized, double-masked, parallel-group study of 139 patients, all of which underwent phacoemulsification and intraocular lens (IOL) implantation. After random assignment, 64 eyes received the combination of topical 0.5% moxifloxacin/0.1% dexamethasone drop and 62 eyes received 0.5% moxifloxacin and 0.1% dexamethasone as separate solutions four times a day for 15 days. Baseline and postoperative assessments were made on surgery days -2, 1, 3, 8, and 15. Limitations of this study included its small size and relatively short duration of follow-up.
  
  
  RESULTS
  There was no sign of intraocular infection at any time and only minimal inflammation beyond day 3. Physicians rated bacterial infection to be absent in both groups on days 1, 3, 8 and 15. Ninety-seven percent of patients in each group had < or = 5 cells by day 15. Objective and subjective parameters were essentially the same in both treatment groups (p > 0.05). One patient in the conventional therapy group developed viral conjunctivitis unrelated to the surgery.
  
  
  CONCLUSIONS
  Treatment with the combined moxiflox acin/dexamethasone eye drops was as effective as conventional treatment in preventing infection and controlling inflammation after phacoemulsification and IOL implantation.
authors.affiliation: Department of Ophthalmology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
authors.forename: Lincoln Lemes
authors.initials: LL
authors.lastname: Freitas
authors.forename: Eduardo
authors.initials: E
authors.lastname: Soriano
authors.forename: Cristina
authors.initials: C
authors.lastname: Muccioli
authors.forename: Ana Luisa
authors.initials: AL
authors.lastname: Höfling-Lima
authors.forename: Rubens
authors.initials: R
authors.lastname: Belfort
mesh_terms: D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001372:Aza Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D019654:Lens Implantation, Intraocular / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D019055:No-Observed-Adverse-Effect Level; D018918:Phacoemulsification / Q000009:adverse effects*; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control*; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000890:Anti-Infective Agents; D018931:Antineoplastic Agents, Hormonal; D001372:Aza Compounds; D004338:Drug Combinations; D024841:Fluoroquinolones; D011804:Quinolines; D003907:Dexamethasone; D000077266:Moxifloxacin